vs
Apellis Pharmaceuticals, Inc.（APLS）与Tecnoglass Inc.（TGLS）财务数据对比。点击上方公司名可切换其他公司
Tecnoglass Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.2倍（$245.3M vs $199.9M），Tecnoglass Inc.净利率更高（10.6% vs -29.5%，领先40.1%），Tecnoglass Inc.同比增速更快（2.4% vs -5.9%），Tecnoglass Inc.自由现金流更多（$11.4M vs $-14.3M），过去两年Tecnoglass Inc.的营收复合增速更高（12.8% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Tecnoglass Inc.是一家领先的建筑玻璃、铝制门窗及相关建材生产商，主要服务北美及拉美地区的住宅和商业建筑领域，为新建及翻新项目提供定制化、高能效的建筑解决方案。
APLS vs TGLS — 直观对比
营收规模更大
TGLS
是对方的1.2倍
$199.9M
营收增速更快
TGLS
高出8.3%
-5.9%
净利率更高
TGLS
高出40.1%
-29.5%
自由现金流更多
TGLS
多$25.7M
$-14.3M
两年增速更快
TGLS
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $245.3M |
| 净利润 | $-59.0M | $26.1M |
| 毛利率 | — | 40.0% |
| 营业利润率 | -25.6% | 18.3% |
| 净利率 | -29.5% | 10.6% |
| 营收同比 | -5.9% | 2.4% |
| 净利润同比 | -62.2% | -44.5% |
| 每股收益（稀释后） | $-0.40 | $0.57 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSTGLS
| Q4 25 | $199.9M | $245.3M | ||
| Q3 25 | $458.6M | $260.5M | ||
| Q2 25 | $178.5M | $255.5M | ||
| Q1 25 | $166.8M | $222.3M | ||
| Q4 24 | $212.5M | $239.6M | ||
| Q3 24 | $196.8M | $238.3M | ||
| Q2 24 | $199.7M | $219.7M | ||
| Q1 24 | $172.3M | $192.6M |
净利润APLSTGLS
| Q4 25 | $-59.0M | $26.1M | ||
| Q3 25 | $215.7M | $47.2M | ||
| Q2 25 | $-42.2M | $44.1M | ||
| Q1 25 | $-92.2M | $42.2M | ||
| Q4 24 | $-36.4M | $47.0M | ||
| Q3 24 | $-57.4M | $49.5M | ||
| Q2 24 | $-37.7M | $35.0M | ||
| Q1 24 | $-66.4M | $29.7M |
毛利率APLSTGLS
| Q4 25 | — | 40.0% | ||
| Q3 25 | — | 42.7% | ||
| Q2 25 | — | 44.7% | ||
| Q1 25 | — | 43.9% | ||
| Q4 24 | — | 44.5% | ||
| Q3 24 | — | 45.8% | ||
| Q2 24 | — | 40.8% | ||
| Q1 24 | — | 38.8% |
营业利润率APLSTGLS
| Q4 25 | -25.6% | 18.3% | ||
| Q3 25 | 48.7% | 25.1% | ||
| Q2 25 | -18.6% | 24.0% | ||
| Q1 25 | -50.0% | 26.7% | ||
| Q4 24 | -12.3% | 28.0% | ||
| Q3 24 | -24.0% | 28.4% | ||
| Q2 24 | -14.7% | 23.3% | ||
| Q1 24 | -36.0% | 21.3% |
净利率APLSTGLS
| Q4 25 | -29.5% | 10.6% | ||
| Q3 25 | 47.0% | 18.1% | ||
| Q2 25 | -23.6% | 17.3% | ||
| Q1 25 | -55.3% | 19.0% | ||
| Q4 24 | -17.1% | 19.6% | ||
| Q3 24 | -29.2% | 20.8% | ||
| Q2 24 | -18.9% | 15.9% | ||
| Q1 24 | -38.5% | 15.4% |
每股收益（稀释后）APLSTGLS
| Q4 25 | $-0.40 | $0.57 | ||
| Q3 25 | $1.67 | $1.01 | ||
| Q2 25 | $-0.33 | $0.94 | ||
| Q1 25 | $-0.74 | $0.90 | ||
| Q4 24 | $-0.30 | $1.00 | ||
| Q3 24 | $-0.46 | $1.05 | ||
| Q2 24 | $-0.30 | $0.75 | ||
| Q1 24 | $-0.54 | $0.63 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $104.1M |
| 总债务越低越好 | — | $174.4M |
| 股东权益账面价值 | $370.1M | $713.1M |
| 总资产 | $1.1B | $1.3B |
| 负债/权益比越低杠杆越低 | — | 0.24× |
8季度趋势，按日历期对齐
现金及短期投资APLSTGLS
| Q4 25 | $466.2M | $104.1M | ||
| Q3 25 | $479.2M | $127.1M | ||
| Q2 25 | $370.0M | $140.9M | ||
| Q1 25 | $358.4M | $160.2M | ||
| Q4 24 | $411.3M | $137.5M | ||
| Q3 24 | $396.9M | $124.8M | ||
| Q2 24 | $360.1M | $129.5M | ||
| Q1 24 | $325.9M | $138.8M |
总债务APLSTGLS
| Q4 25 | — | $174.4M | ||
| Q3 25 | — | $114.7M | ||
| Q2 25 | — | $110.6M | ||
| Q1 25 | — | $110.6M | ||
| Q4 24 | — | $111.1M | ||
| Q3 24 | — | $126.8M | ||
| Q2 24 | — | $144.7M | ||
| Q1 24 | $93.1M | $160.9M |
股东权益APLSTGLS
| Q4 25 | $370.1M | $713.1M | ||
| Q3 25 | $401.2M | $764.0M | ||
| Q2 25 | $156.3M | $736.0M | ||
| Q1 25 | $164.2M | $685.1M | ||
| Q4 24 | $228.5M | $631.2M | ||
| Q3 24 | $237.1M | $613.3M | ||
| Q2 24 | $264.3M | $574.8M | ||
| Q1 24 | $266.7M | $573.6M |
总资产APLSTGLS
| Q4 25 | $1.1B | $1.3B | ||
| Q3 25 | $1.1B | $1.2B | ||
| Q2 25 | $821.4M | $1.2B | ||
| Q1 25 | $807.3M | $1.1B | ||
| Q4 24 | $885.1M | $1.0B | ||
| Q3 24 | $901.9M | $996.3M | ||
| Q2 24 | $904.5M | $942.5M | ||
| Q1 24 | $831.9M | $981.6M |
负债/权益比APLSTGLS
| Q4 25 | — | 0.24× | ||
| Q3 25 | — | 0.15× | ||
| Q2 25 | — | 0.15× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.18× | ||
| Q3 24 | — | 0.21× | ||
| Q2 24 | — | 0.25× | ||
| Q1 24 | 0.35× | 0.28× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $31.0M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $11.4M |
| 自由现金流率自由现金流/营收 | -7.1% | 4.7% |
| 资本支出强度资本支出/营收 | 0.1% | 8.0% |
| 现金转化率经营现金流/净利润 | — | 1.19× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $34.5M |
8季度趋势，按日历期对齐
经营现金流APLSTGLS
| Q4 25 | $-14.2M | $31.0M | ||
| Q3 25 | $108.5M | $40.0M | ||
| Q2 25 | $4.4M | $17.9M | ||
| Q1 25 | $-53.4M | $46.9M | ||
| Q4 24 | $19.4M | $61.1M | ||
| Q3 24 | $34.1M | $41.5M | ||
| Q2 24 | $-8.3M | $34.5M | ||
| Q1 24 | $-133.0M | $33.4M |
自由现金流APLSTGLS
| Q4 25 | $-14.3M | $11.4M | ||
| Q3 25 | $108.3M | $21.2M | ||
| Q2 25 | $4.4M | $-14.7M | ||
| Q1 25 | $-53.4M | $16.5M | ||
| Q4 24 | $19.3M | $35.4M | ||
| Q3 24 | — | $17.8M | ||
| Q2 24 | $-8.4M | $14.2M | ||
| Q1 24 | $-133.3M | $23.6M |
自由现金流率APLSTGLS
| Q4 25 | -7.1% | 4.7% | ||
| Q3 25 | 23.6% | 8.2% | ||
| Q2 25 | 2.5% | -5.7% | ||
| Q1 25 | -32.0% | 7.4% | ||
| Q4 24 | 9.1% | 14.8% | ||
| Q3 24 | — | 7.5% | ||
| Q2 24 | -4.2% | 6.5% | ||
| Q1 24 | -77.3% | 12.2% |
资本支出强度APLSTGLS
| Q4 25 | 0.1% | 8.0% | ||
| Q3 25 | 0.0% | 7.2% | ||
| Q2 25 | 0.0% | 12.7% | ||
| Q1 25 | 0.0% | 13.7% | ||
| Q4 24 | 0.0% | 10.7% | ||
| Q3 24 | 0.0% | 9.9% | ||
| Q2 24 | 0.0% | 9.2% | ||
| Q1 24 | 0.2% | 5.1% |
现金转化率APLSTGLS
| Q4 25 | — | 1.19× | ||
| Q3 25 | 0.50× | 0.85× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 1.11× | ||
| Q4 24 | — | 1.30× | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | — | 0.98× | ||
| Q1 24 | — | 1.13× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
TGLS
| Product Sales | $164.2M | 67% |
| Fixed Price Contracts | $81.1M | 33% |
| Related Party | $692.0K | 0% |
